Craig D. Wegner
About
In The Last Decade
Craig D. Wegner
54 papers receiving 3.2k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Immunology 1.1k
- Physiology 940
- Molecular Biology 857
- Immunology and Allergy 723
- Oncology 703
Countries citing papers authored by Craig D. Wegner
This map shows the geographic impact of Craig D. Wegner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig D. Wegner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig D. Wegner more than expected).
Fields of papers citing papers by Craig D. Wegner
This network shows the impact of papers produced by Craig D. Wegner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig D. Wegner. The network helps show where Craig D. Wegner may publish in the future.
Co-authorship network of co-authors of Craig D. Wegner
This figure shows the co-authorship network connecting the top 25 collaborators of Craig D. Wegner. A scholar is included among the top collaborators of Craig D. Wegner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig D. Wegner. Craig D. Wegner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 32 | |
| 2 | 37 | |
| 3 | Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses breakdown → | 759 |
| 4 | Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival breakdown → | 463 |
| 5 | 11 | |
| 6 | 16 | |
| 7 | 38 | |
| 8 | 34 | |
| 9 | 72 | |
| 10 | 4 | |
| 11 | 3 | |
| 12 | 55 | |
| 13 | 61 | |
| 14 | 5 | |
| 15 | 47 | |
| 16 | 194 | |
| 17 | 5 | |
| 18 | 15 | |
| 19 | 30 | |
| 20 | 3 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.